Jefferies Financial Group Inc. recently released an outlook report on the US biotech industry for 2026, focusing on top investment picks, undervalued companies, and potential merger opportunities. The report highlights that 2026 will see key clinical trial data disclosures, new drug approvals, and policy developments, with companies poised for revaluation due to technological breakthroughs and commercialization progress.

**Six Top Picks** Jefferies selected six companies as core recommendations for 2026 based on market catalysts and valuation potential: 1. **Dianthus Therapeutics (DNTH.US)**, target price $66: Its lead drug, claseprubart (a C1s inhibitor), shows promise in neuromuscular diseases like CIDP, gMG, and MMN, with peak sales potential of $2 billion. Key 2026 milestones include Phase III interim analysis for CIDP and Phase III trial initiation for gMG. 2. **Taysha Gene Therapies (TSHA.US)**, target price $11: Gene therapy TSHA-102 for Rett syndrome has significant market potential ($2 billion peak sales). Its intrathecal delivery offers safety advantages. Phase III 6-month interim data is expected in late 2026. 3. **Tyra Biosciences (TYRA.US)**, target price $32: Oral FGFR3 inhibitor dabogratinib (TYRA-300) could disrupt IR-NMIBC and ACH treatments. Key data for both indications will be released in 2026. 4. **Tango Therapeutics (TNGX.US)**, target price $14: Its PRMT5 inhibitor vopimetostat, combined with RAS inhibitors, may revolutionize MTAP-deleted pancreatic cancer treatment. Data is expected in H1 2026. 5. **ORIC Pharmaceuticals (ORIC.US)**, target price $23: Features two assets—PRC2 inhibitor ORIC-944 for prostate cancer and enzertinib for EGFR/PACC-mutant lung cancer. Key 2026 catalysts include ORIC-944 dose optimization and enzertinib updates. 6. **Solid Biosciences (SLDB.US)**, target price $15: Focused on DMD gene therapy SGT-003, with three FDA meetings in H1 2026 to finalize Phase III trial design.

**Seven Undervalued Stocks** Jefferies identified seven undervalued companies with significant catalysts: 1. **Ultragenyx Pharmaceutical (RARE.US)**, target price $114: Setrusumab (osteogenesis imperfecta) Phase III data in late 2025/early 2026 could drive a 100% stock surge. GTX-102 (Angelman syndrome) data is due in H2 2026. 2. **Beam Therapeutics (BEAM.US)**, target price $41: BEAM-302 (AATD) shows best-in-class potential with 91% mutation correction. SCD therapy BEAM-101 may file for approval in late 2026. 3. **Aurinia Pharmaceuticals (AUPH.US)**, target price $21: Lupkynis (lupus nephritis) is growing steadily. Aritinercept (autoimmune diseases) development path will be announced in early 2026. 4. **Kodiak Sciences (KOD.US)**, target price $39: Retinal disease therapy KSI-101’s Phase III data could trigger a 40%-60% stock move. 5. **Intellia Therapeutics (NTLA.US)**, target price $45: Lonvo-z (HAE) data in mid-2026 may reinforce its gene-editing leadership. 6. **Compass Therapeutics (CMPX.US)**, target price $8: Tovecimab (cholangiocarcinoma) durability data in Q1 2026 could establish it as a second-line standard. 7. **KalVista Pharmaceuticals (KALV.US)**, target price $38: Oral HAE drug Ekterly, launched 1.5-2 years ahead of rivals, may drive rapid revenue growth ($700M peak sales).

**Five M&A Targets** Jefferies flagged these companies as potential 2026 acquisition targets: 1. **Arrowhead Pharmaceuticals (ARWR.US)**: Strong RNAi pipeline for cardiometabolic diseases and obesity. 2. **Celcuity (CELC.US)**: Gedatolisib shows unique efficacy in PIK3CA wild-type breast cancer. 3. **ORIC Pharmaceuticals**: High-value prostate/lung cancer programs. 4. **Travere Therapeutics (TVTX.US)**: FSGS approval could unlock rare kidney disease markets. 5. **KalVista Pharmaceuticals**: First-mover advantage in oral HAE therapy.